Company / EPS (Diluted)
LENZ Therapeutics, Inc. EPS (Diluted) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$2.34
FY2025
5-year range
-$35.71 / -$1.84
FY2021-FY2025
Trend
+0.0%
vs FY2024
Sector context
#136 of 204
Health Care
What the data says
At $-2.34, LENZ Therapeutics, Inc.'s eps (diluted) ranks #136 of 204 in the Health Care sector. Improved from $-35.71 to $-2.34 over the past 2 years.
Based on SEC 10-K filings.
-2.34 in FY2025.
Improved from $-35.71 to $-2.34 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#136 of 204 in Health CareTop 67% of 204This company -$2.34 Sector average -$0.89
▼
-164.0% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 0.0% year-over-year.
- Ranks #136 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2022.
- Lowest eps (diluted) in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.71 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.34 | +0.0% |
| FY2024 | -$2.34 | +93.4% |
| FY2023 | -$35.71 | -1840.8% |
| FY2022 | -$1.84 | +24.9% |
| FY2021 | -$2.45 | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026